University Research Center Seeks Federal Permission to Import Marijuana
Published Date: 10/19/2026
Notice
Summary
The National Center for Natural Products Research wants to become an official importer of certain controlled substances, like marijuana. People and companies involved can share their thoughts or ask for a hearing by November 18, 2026. This move could impact researchers and businesses working with these substances, but no costs or fees are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Finished Dosage Forms Not Authorized for Import
The registration application, if approved, will not authorize the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Approval will be limited to activities consistent with 21 U.S.C. 952(a)(2).
Application to Import Schedule I Cannabis Materials
The National Center for Natural Products Research applied on September 7, 2026 to be registered as an importer of marihuana (drug code 7360, Schedule I) and tetrahydrocannabinols (drug code 7370, Schedule I). The applicant says it plans to acquire new genetic materials with different cannabinoid profiles for research and manufacturing purposes, and no other activities for these drug codes are authorized under this registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-21354, Importer of Controlled Substances Application: DMS Pharmaceutical Group
DMS Pharmaceutical Group wants to become an official importer of fentanyl, a powerful controlled substance. People and companies involved with these drugs can share their thoughts or ask for a hearing by November 18, 2026. This move could impact how fentanyl is brought into the U.S., so keep an eye on the deadline if you’re involved!
2026-21369, Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals wants to officially make a big batch of methylphenidate, a controlled drug, at their Georgia site. People who already make or use this drug can share their thoughts or ask for a hearing by December 18, 2026. This move could affect how the drug is produced and sold, but no extra activities are allowed beyond manufacturing for sale.
Previous / Next Documents
Previous: 2026-21357, Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Services Surveys: BE-125, Quarterly Survey of Transactions in Selected Services and Intellectual Property With Foreign Persons
The Department of Commerce wants your thoughts on a survey that collects info from U.S. businesses dealing with foreign folks in services and intellectual property. If your sales with foreign partners hit $6 million or more, this affects you! They’re asking for comments by December 18, 2026, to keep the survey smooth and useful without wasting anyone’s time or money.
Next: 2026-21359, Bulk Manufacturer of Controlled Substances Application: National Center for Natural Products Research University of Mississippi/NCNPR
The National Center for Natural Products Research at the University of Mississippi wants to officially make large amounts of marijuana and related substances for research and product development. People who might be affected can share their thoughts or ask for a hearing by December 18, 2026. This move helps support scientific progress while keeping safety rules in check.